ArticleDermatology and therapy2024

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis.

April W Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.